- Home
- SUUN vs SGMT Comparison
SUUN vs SGMT Comparison
Compare SUUN & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUUN
- SGMT
- Stock Information
- Founded
- SUUN 2013
- SGMT 2006
- Country
- SUUN Canada
- SGMT United States
- Employees
- SUUN N/A
- SGMT N/A
- Industry
- SUUN
- SGMT
- Sector
- SUUN
- SGMT
- Exchange
- SUUN Nasdaq
- SGMT Nasdaq
- Market Cap
- SUUN 75.1M
- SGMT 71.2M
- IPO Year
- SUUN N/A
- SGMT 2023
- Fundamental
- Price
- SUUN $1.83
- SGMT $3.22
- Analyst Decision
- SUUN Strong Buy
- SGMT Strong Buy
- Analyst Count
- SUUN 1
- SGMT 6
- Target Price
- SUUN $6.00
- SGMT $25.67
- AVG Volume (30 Days)
- SUUN 146.8K
- SGMT 554.9K
- Earning Date
- SUUN 05-15-2025
- SGMT 05-08-2025
- Dividend Yield
- SUUN N/A
- SGMT N/A
- EPS Growth
- SUUN N/A
- SGMT N/A
- EPS
- SUUN N/A
- SGMT N/A
- Revenue
- SUUN $36,247,013.00
- SGMT N/A
- Revenue This Year
- SUUN $15.42
- SGMT N/A
- Revenue Next Year
- SUUN $62.53
- SGMT N/A
- P/E Ratio
- SUUN N/A
- SGMT N/A
- Revenue Growth
- SUUN 43.76
- SGMT N/A
- 52 Week Low
- SUUN $1.95
- SGMT $1.73
- 52 Week High
- SUUN $6.87
- SGMT $7.38
- Technical
- Relative Strength Index (RSI)
- SUUN 29.67
- SGMT 51.20
- Support Level
- SUUN $1.96
- SGMT $3.08
- Resistance Level
- SUUN $2.05
- SGMT $3.48
- Average True Range (ATR)
- SUUN 0.15
- SGMT 0.27
- MACD
- SUUN 0.02
- SGMT -0.01
- Stochastic Oscillator
- SUUN 7.00
- SGMT 13.46
About SUUN SolarBank Corporation Common Stock
SolarBank Corp is an independent renewable and clean energy project developer and asset operator based in Canada and the United States. It is engaged in the development and operation of solar photovoltaic power generation projects in the province of Ontario and the state of New York. The company operates in two principal geographical areas - Canada and United States with a substantial portion of its overall revenue being generated from United States.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.